| Project Detail |
The project finances the borrowers expenditures over the next three years related to Masitinib and its analogues against COVID-19 (non-clinical and clinical studies, drug manufacturing including stock piling, related regulatory expenses, related general and administrative (G&A) expenses).The project will be implemented from Paris, France.
Objectives
The project finances the borrowers expenditures over the next three years related to Masitinib and its analogues against COVID-19 (non-clinical and clinical studies, drug manufacturing including stock piling, related regulatory expenses, related G&A expenses).The project will be implemented from Paris, France. The companys innovative approach might prevent complications linked to severe pulmonary inflammation and thrombotic events potentially leading to death. It also aims to reduce the burden on intensive care units and more invasive treatment options. By co-investing in the project, the Bank contributes to improving healthcare, whilst also fostering the generation of European scientific knowledge and acumen, preserving and cultivating highly skilled employment opportunities.
Sector(s)
Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 15 million
Total cost (Approximate amount)
EUR 35 million |
